SPOTLIGHT: Trial failure hits Evolutec
The Times is reporting that Evolutec is being put up on the sales block following the failure of its lead candidate in a mid-stage trial. Researchers for the company said that rEV131 had failed to reduce inflammation in patients following cataract surgery. The company has a market capitalization of 4 million pounds sterling. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
